Skip to main content

Advertisement

Table 3 Description of methylation status by methylation-specific PCR (MSP) in relation to main demographic and clinical parameters

From: Recurrence in oral and pharyngeal cancer is associated with quantitative MGMT promoter methylation

  MGMTMethylation (%) RASSF1methylation (%) CDKN2Amethylation (%)
Gender    
   Male 14/56 (25.0%) 4/44 (9.1%) 5/40 (12.5%)
   Female 12/32 (37.5%) 4/22 (18.2%) 2/21 (9.5%)
Smoking status    
   Never smoker 5/11 (45.5%) 0/9 (0.0%) 2/8 (25.0%)
   Ever smoker 21/77 (27.3%) 8/57 (14.0%) 5/53 (9.4%)
Alcohol use    
   Never drinker 4/16 (25.0%) 0/12 (0.0%) 4/12 (33.3%)*
   Ever drinker 22/72 (30.6%) 8/54 (14.8%) 3/49 (6.1%)*
Family history    
   Negative 11/41 (26.8%) 3/35 (8.6%) 4/30 (13.3%)
   Positive 15/47 (31.9%) 5/31 (16.1%) 3/31 (9.7%)
Histology    
   Squamous 24/85 (28.2%) 8/65 (12.3%) 7/60 (11.7%)
   Other 2/3 (66.7%) 0/1 (0.0%) 0/1 (0.0%)
Anatomic site    
   Oral cavity & lip 12/50 (24.0%) 5/37 (13.5%) 6/35 (17.1%)
   Oropharynx 14/38 (36.8%) 3/29 (10.3%) 1/26 (3.8%)
Stage at diagnosis    
   Local (I, II) 11/36 (30.6%) 5/27 (18.5%) 4/26 (15.4%)*
   Advanced (III, IV) 15/52 (28.8%) 3/39 (7.7%) 3/35 (8.6%)*
Treatment    
   Surgery only 9/44 (20.5%) 3/26 (11.5%) 3/24 (12.5%)
   Surgery and radiotherapy 16/39 (41.0%) 5/40 (12.5%) 4/37 (10.8%)
   Surgery and chemoradiation 1/5 (20.0%) ----- -----
HPV    
   Negative 18/67 (26.9%) 7/47 (14.9%) 7/45 (15.6%)
   Positive 8/21 (38.1%) 1/19 (5.3%) 0/7 (0.0%)
  1. * Statistically significant (α = 0.05)